Buy Like Buffett
Watchlist

Flagship explainer

How CYTOSORBENTS CORPORATION makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$37.1M · 100%Cost of revenue$10.6M · 29%Gross profit$26.5M · 71%Operating income−$14.7M · −40%Income before tax−$8.6M · −23%Income tax−$401000 · −1%Net income−$8.2M · −22%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$37.1M100%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036451 · filed Mar 30, 2026
Cost of revenue$10.6M29%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036451 · filed Mar 30, 2026
$26.5M71%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036451 · filed Mar 30, 2026
−$14.7M−40%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036451 · filed Mar 30, 2026
Income before tax−$8.6M−23%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036451 · filed Mar 30, 2026
Income tax−$401000−1%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036451 · filed Mar 30, 2026
−$8.2M−22%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036451 · filed Mar 30, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036451 · filed Mar 30, 2026
· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set
Embed this chart

View the full CYTOSORBENTS CORPORATION analysis at Buy Like Buffett